https://www.selleckchem.com/products/af353.html
For donor lymphocyte infusion, bortezomib or lenalidomide have been used as consolidation or maintenance therapies post-transplant-none has become standard of care. For those patients who relapse, the best treatment should be evaluated considering the patient's clinical status and the previous lines of therapy. The use of newer drugs, such as monoclonal antibodies or other immunotherapies in the post-transplant setting, deserves further investigation. However, acceptable toxicity and a synergic effect with the newer immune system could be
Respect!
Kommentar
Delen
